New scan could spot myeloma lesions better than current tests
NCT ID NCT07353554
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests a new type of PET/CT scan that uses a special tracer (68Ga-BCMA nanobody) to find multiple myeloma lesions in the body. Researchers will compare it to the standard FDG-PET/CT scan in 30 patients with newly diagnosed or relapsed multiple myeloma. The goal is to see if the new method detects more lesions and helps predict how the disease will progress.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
68Ga-NOTA-BCMA nanobody (a radioactive tracer for PET/CT imaging)
What this could lead to
If successful, this could provide a more sensitive and specific imaging test for multiple myeloma, helping doctors detect disease earlier and choose better treatments.
What could go wrong
This is a small, early-phase study with only 30 participants, so results may not apply to all patients. The new tracer may not detect all lesions or may have unexpected side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA (MM) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Peking Union Medical College
Beijing, 100730, China
Contact Phone: •••-•••-••••